Aclaris Therapeutics Q2 EPS $(0.42) Beats $(0.45) Estimate, Sales $1.87M Miss $1.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics reported Q2 earnings per share (EPS) of $(0.42), beating the estimate of $(0.45) by 6.67%. However, the company's sales of $1.87M missed the estimate of $1.90M by 1.63%. The EPS is a 35.48% decrease from last year, while sales increased by 22.32% from the same period last year.
August 07, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aclaris Therapeutics' Q2 EPS beat estimates but sales missed. The EPS decreased by 35.48% YoY, while sales increased by 22.32% YoY.
Aclaris Therapeutics reported mixed Q2 results with EPS beating estimates but sales missing. The decrease in EPS YoY indicates profitability issues, while the increase in sales suggests growth. This could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100